Skip to content
Screener

Theravance Biopharma TBPH Q4 2025 Annual earnings

Reported March 19, 2026 · Before market open

Revenue$45.9MMiss by $10.7M
EPS$0.06Miss by $0.38
Revenue estimate$56.6M
EPS estimate$0.44

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$22.0M
EPS estimate$0.24

Financials

Q4 2025

Income statement

See full
Revenue$45.9M+145%
Operating income$20.0M+318%
Net income$61.0M+493%
EPS (diluted)$1.15+471%

Balance sheet

See full
Cash & equivalents$167.8M+344%
Total debt$42.7M-14.3%
Total equity$296.7M+69.0%
Total assets$485.6M+37.1%

Cash flow

See full
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$948.08M+105%
Enterprise value$822.98M+73.3%
P/E9×—
P/S8.8×+1.6×

Profitability

See full
Operating margin-3.4%-1.6pp
Net margin98.5%+67.0pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity44.8%+32.2pp
Debt / equity0.1×-0.1×
Current ratio10.9×+5.9×

Segments

By segment

See full
Single Reportable$45.9M+145%

By product

See full
Collaborative Arrangement Revenue$20.9M+11.4%

FAQ

When did Theravance Biopharma report Q4 2025 earnings?
Theravance Biopharma (TBPH) reported Q4 2025 earnings on March 19, 2026 before market open.
What were Theravance Biopharma's Q4 2025 revenue and EPS?
Theravance Biopharma reported revenue of $45.9M and eps of $0.06 for Q4 2025.
Did Theravance Biopharma beat estimates in Q4 2025?
Revenue missed the consensus estimate of $56.6M by $10.7M. EPS missed the consensus estimate of $0.44 by $0.38.
How did Theravance Biopharma's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 144.7% from $18.8M a year earlier.
Where can I find Theravance Biopharma's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-031795) and the 10-K periodic report (0001104659-26-033077) directly on SEC EDGAR. The filing index links above go to sec.gov.